Blueprint Medicines Corporation

NASDAQ:BPMC

129.46 (USD) • At close July 18, 2025
Bedrijfsnaam Blueprint Medicines Corporation
Symbool BPMC
Munteenheid USD
Prijs 129.46
Beurswaarde 8,360,811,612
Dividendpercentage 0%
52-weken bereik 73.04 - 129.55
Industrie Biotechnology
Sector Healthcare
CEO Ms. Kathryn Haviland
Website https://www.blueprintmedicines.com

An error occurred while fetching data.

Over Blueprint Medicines Corporation

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of

Vergelijkbare Aandelen

Cytokinetics, Incorporated logo

Cytokinetics, Incorporated

CYTK

37.18 USD

CureVac N.V. logo

CureVac N.V.

CVAC

5.46 USD

Inari Medical, Inc. logo

Inari Medical, Inc.

NARI

79.97 USD

Ultragenyx Pharmaceutical Inc. logo

Ultragenyx Pharmaceutical Inc.

RARE

27.34 USD

Intellia Therapeutics, Inc. logo

Intellia Therapeutics, Inc.

NTLA

13.595 USD

Merit Medical Systems, Inc. logo

Merit Medical Systems, Inc.

MMSI

84.69 USD

Mirati Therapeutics, Inc. logo

Mirati Therapeutics, Inc.

MRTX

58.7 USD

Natera, Inc. logo

Natera, Inc.

NTRA

138.9 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)